Next Article in Journal
cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
Previous Article in Journal
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells
Open AccessReview

Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets

Department of Neurosurgery, New York Medical College, Valhalla, NY 10595, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Brigitta G. Baumert
Cancers 2015, 7(2), 538-555; https://doi.org/10.3390/cancers7020538
Received: 11 July 2014 / Revised: 12 February 2015 / Accepted: 9 March 2015 / Published: 25 March 2015
Glioblastoma (GBM), a WHO-defined Grade IV astrocytoma, is the most common and aggressive CNS malignancy. Despite current treatment modalities, the survival time remains dismal. The main cause of mortality in patients with this disease is reoccurrence of the malignancy, which is attributed to treatment-resistant cancer stem cells within and surrounding the primary tumor. Inclusion of novel therapies, such as immuno- and DNA-based therapy, may provide better means of treating GBM. Furthermore, manipulation of recently discovered non-coding microRNAs, some of which regulate tumor growth through the development and maintenance of GBM stem cells, could provide new prospective therapies. Studies conducted by The Cancer Genome Atlas (TCGA) also demonstrate the role of molecular pathways, specifically the activated PI3K/AKT/mTOR pathway, in GBM tumorigenesis. Inhibition of the aforementioned pathway may provide a more direct and targeted method to GBM treatment. The combination of these treatment modalities may provide an innovative therapeutic approach for the management of GBM. View Full-Text
Keywords: brain tumors; GBM; cancer stem cells; mTOR; therapies brain tumors; GBM; cancer stem cells; mTOR; therapies
Show Figures

Figure 1

MDPI and ACS Style

Jhanwar-Uniyal, M.; Labagnara, M.; Friedman, M.; Kwasnicki, A.; Murali, R. Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets. Cancers 2015, 7, 538-555.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop